Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus

Abstract

OBJECTIVES: To assess the effect of two doses, i.e., 10 mg and 25 mg of empagliflozin, on the lipid profile of patients with type 2 diabetes mellitus (T2DM) with suboptimal glycemic control on maximal doses of metformin and sitagliptin. METHODOLOGY: The study design was a randomized, open-label clinical trial. Fifty-nine adult patients of T2DM who were already on 2000 mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycaemic control (HBA1C > 7% 0.05). CONCLUSION: Both doses of Empagliflozin (10 and 25 mg) modestly elevates total cholesterol, LDL-C and HDL-C and modestly reduce triglyceride levels in T2DM patients, but the change is not statistically significant. KEYWORDS: Empagliflozin, Type 2 diabetes mellitus, Total cholesterol, Low-density cholesterol, High-density cholesterol, Triglycerides

Keywords

• Type 2 diabetes mellitus
• Empagliflozin
• Total choelsterol
• High-density cholesterol
• Low-density cholesterol
• Triglycerides